Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-450-6864555
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Acasti Pharma (CVE:ACST) Frequently Asked Questions
What is Acasti Pharma's stock symbol?
Acasti Pharma trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ACST."
Has Acasti Pharma been receiving favorable news coverage?
Media coverage about ACST stock has been trending negative recently, InfoTrie Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Acasti Pharma earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future.
Who are some of Acasti Pharma's key competitors?
Some companies that are related to Acasti Pharma include Starpharma (SPL), Neptune Wellness Solutions (NEPT), IMV (IMV), Enochian Biosciences (ENOB), Monash IVF Group (MVF), Kodiak Sciences (KOD), Horizon Discovery Group (HZD), Emblem (EMC), 22nd Century Group (XXII), ProMetic Life Sciences (PLI), BELLUS Health (BLU), MediGene (MDG1), IMV (IMV), BioTime (BTX) and Bioventix (BVXP).
What other stocks do shareholders of Acasti Pharma own?
Who are Acasti Pharma's key executives?
Acasti Pharma's management team includes the folowing people:
- Ms. Janelle D' Alvise, Pres, CEO & Director
- Dr. Pierre Lemieux, Chief Operating Officer
- Mr. Jean-François Boily, VP of Fin.
- Mr. Brian James Groch, Chief Commercial Officer (Age 52)
How do I buy shares of Acasti Pharma?
Shares of ACST and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Acasti Pharma's stock price today?
One share of ACST stock can currently be purchased for approximately C$1.42.
How big of a company is Acasti Pharma?
Acasti Pharma has a market capitalization of C$110.94 million.
What is Acasti Pharma's official website?
How can I contact Acasti Pharma?
Acasti Pharma's mailing address is 545 Prom du Centropolis Suite 100, LAVAL, QC H7T 0A3, Canada. The company can be reached via phone at +1-450-6864555.
MarketBeat Community Rating for Acasti Pharma (CVE ACST)
MarketBeat's community ratings are surveys of what our community members think about Acasti Pharma and other stocks. Vote "Outperform" if you believe ACST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACST will underperform the S&P 500 over the long term. You may vote once every thirty days.
